RecruitingPhase 2NCT07806292

Anlotinib + Benmelstobart + HAIC in Unresectable HCC: A Phase II Study

A Single-arm, Multicenter, Phase II Clinical Study of Anlotinib Combined With Benmelstobart and HAIC as First-line Treatment for Unresectable Hepatocellular Carcinoma

Sponsor

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Enrollment

30 participants

Start Date

Apr 28, 2025

Study Type

INTERVENTIONAL

Conditions

Unresectable Hepatocellular Carcinoma

Summary

To evaluate the efficacy and safety of anlotinib combined with benmelstobart and HAIC as first-line treatment for unresectable hepatocellular carcinoma.

Eligibility

Min Age: 18 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called anlotinib combined with benmelstobart and HAIC for people with unresectable hepatocellular carcinoma. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years to 75 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGanlotinib combined with benmelstobart and HAIC

HAIC with FOLFOX (oxaliplatin 85 mg/m², leucovorin 400 mg/m², 5-fluorouracil 400 mg/m² bolus followed by 2400 mg/m² over 23 h) plus oral anlotinib 10 mg (d1-14) and intravenous benmelstobart 1200 mg (d1) every 3 weeks

Locations(1)

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Guangzhou, Guangdong, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07806292

Related Trials

Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors

NCT052693811 location

Symbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatment in Adult Participants With a Liver Cancer Called Hepatocellular Carcinoma, That is Too Advanced to be Removed by Surgery and May Have Spread to Other Parts of the Body.

NCT0722701249 locations

Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer

NCT0516816316 locations

Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) Combined With Immune Checkpoint Inhibition After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver Cancer

NCT039423281 location

First-Line Nivolumab Plus Ipilimumab in Unresectable Hepatocellular Carcinoma (J-PROMISE)

NCT076790612 locations